Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Shares Jump 115 Percent Following IPO

NEW YORK, Sept 29 – Shares of chipmaker Ciphergen Biosystems (Nasdaq: CIPH) shot up more than 115 percent in their first day of trading on the Nasdaq on Friday.

The Fremont, Calif.-based company offered 5.5 million shares of its common stock for $16 per share. The offering, which was priced at the high-end of the $14-$16 range, raised $88 million.

In afternoon trading the shares were up 18 1/2, or 115.6 percent, at 34 1/2.

SG Cowen, was the lead managing underwriter and ING Barings and Warburg Dillon Read were co-managers.

Ciphergen has granted the underwriters the option to purchase an additional 750,000 shares of its common stock to cover over-allotments.

Ciphergen develops, manufactures and markets the ProteinChip System, which enables protein discovery, characterization and assay development to provide researchers with a better understanding of biological functions at the protein level.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.